MedTrace Logo

BurstDR™ micrOdosing stimuLation in De-novo Patients

NCT03350256 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2020-03-19

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the therapeutic efficacy of microdosing BurstDR stimulation in spinal cord stimulation (SCS) patients with chronic intractable back and/or leg pain.

Conditions

  • Pain, Intractable
  • Pain, Back

Interventions

DEVICE

Stimulation will be delivered at with different microdosing setting to identify the optimal parameter values for each patient.

BurstDR spinal cord stimulation will be delivered with different ON/OFF periods to identify the best setting for each patients.

Sponsors & Collaborators

  • Abbott Medical Devices

    lead INDUSTRY

Principal Investigators

  • Timothy R Deer, MD · The Center for Pain Relief

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-30
Primary Completion
2019-07-02
Completion
2019-07-02
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03350256 on ClinicalTrials.gov